A Phase 1, Multicenter, Open-label, Dose-Finding Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection of INS1202 in Patients With Amyotrophic Lateral Sclerosis
Latest Information Update: 09 Feb 2026
At a glance
- Drugs INS 1202 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms ARMOR
- Sponsors Insmed
Most Recent Events
- 04 Feb 2026 Status changed from not yet recruiting to recruiting.
- 24 Dec 2025 New trial record